An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients
Top Cited Papers
- 1 January 2011
- journal article
- other
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 183 (1), 96-128
- https://doi.org/10.1164/rccm.2008-740st
Abstract
With increasing numbers of immune-compromised patients with malignancy, hematologic disease, and HIV, as well as those receiving immunosupressive drug regimens for the management of organ transplantation or autoimmune inflammatory conditions, the incidence of fungal infections has dramatically increased over recent years. Definitive diagnosis of pulmonary fungal infections has also been substantially assisted by the development of newer diagnostic methods and techniques, including the use of antigen detection, polymerase chain reaction, serologies, computed tomography and positron emission tomography scans, bronchoscopy, mediastinoscopy, and video-assisted thorascopic biopsy. At the same time, the introduction of new treatment modalities has significantly broadened options available to physicians who treat these conditions. While traditionally antifungal therapy was limited to the use of amphotericin B, flucytosine, and a handful of clinically available azole agents, current pharmacologic treatment options include potent new azole compounds with extended antifungal activity, lipid forms of amphotericin B, and newer antifungal drugs, including the echinocandins. In view of the changing treatment of pulmonary fungal infections, the American Thoracic Society convened a working group of experts in fungal infections to develop a concise clinical statement of current therapeutic options for those fungal infections of particular relevance to pulmonary and critical care practice. This document focuses on three primary areas of concern: the endemic mycoses, including histoplasmosis, sporotrichosis, blastomycosis, and coccidioidomycosis; fungal infections of special concern for immune-compromised and critically ill patients, including cryptococcosis, aspergillosis, candidiasis, and Pneumocystis pneumonia; and rare and emerging fungal infections.Keywords
This publication has 288 references indexed in Scilit:
- Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care settingEuropean Journal of Clinical Microbiology & Infectious Diseases, 2007
- Treatment of Severe Candida Infections in High-Risk Patients in Germany: Consensus Formed by a Panel of Interdisciplinary InvestigatorsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2002
- High Rates of Pneumocystis carinii Pneumonia in Allogeneic Blood and Marrow Transplant Recipients Receiving Dapsone ProphylaxisClinical Infectious Diseases, 1999
- Blastomycosis of the lumbar spine: case report and review of the literature, with emphasis on diagnostic laboratory tools and managementEuropean Spine Journal, 1998
- Itraconazole therapy in aspergillosis: Study in 49 patientsJournal of the American Academy of Dermatology, 1990
- Itraconazole treatment of phaeohyphomycosisJournal of the American Academy of Dermatology, 1990
- Treatment of Cryptococcal Meningitis with Combination Amphotericin B and Flucytosine for Four as Compared with Six WeeksThe New England Journal of Medicine, 1987
- Successful Intermittent Chemoprophylaxis forPneumocystis cariniiPneumonitisThe New England Journal of Medicine, 1987
- Lethal Pulmonary Reactions Associated with the Combined Use of Amphotericin B and Leukocyte TransfusionsThe New England Journal of Medicine, 1981
- A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal MeningitisThe New England Journal of Medicine, 1979